Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $40.26, for a total value of $805,200.00. Following the completion of the transaction, the executive vice president directly owned 20,000 shares of the company’s stock, valued at approximately $805,200. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Marshall Urist also recently made the following trade(s):

• On Friday, January 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.52, for a total transaction of $790,400.00.
• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $40.78, for a total transaction of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.32, for a total transaction of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total transaction of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total transaction of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Stock Up 0.7%

RPRX stock opened at $40.74 on Wednesday. The company has a market cap of $23.52 billion, a price-to-earnings ratio of 30.86, a P/E/G ratio of 1.55 and a beta of 0.43. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The business’s 50-day moving average is $39.40 and its two-hundred day moving average is $37.64. Royalty Pharma PLC has a fifty-two week low of $29.66 and a fifty-two week high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. As a group, analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be given a $0.235 dividend. The ex-dividend date is Friday, February 20th. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a yield of 2.3%. Royalty Pharma’s payout ratio is 66.67%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Nordea Investment Management AB lifted its stake in shares of Royalty Pharma by 603.9% during the 2nd quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company’s stock worth $23,701,000 after purchasing an additional 562,799 shares during the last quarter. Watchtower Advisors LP bought a new position in Royalty Pharma in the second quarter worth about $3,603,000. World Investment Advisors purchased a new stake in shares of Royalty Pharma during the third quarter valued at about $1,702,000. Financiere des Professionnels Fonds d investissement inc. purchased a new stake in shares of Royalty Pharma during the third quarter valued at about $933,000. Finally, Generali Asset Management SPA SGR boosted its holdings in shares of Royalty Pharma by 7,752.8% in the 3rd quarter. Generali Asset Management SPA SGR now owns 34,081 shares of the biopharmaceutical company’s stock valued at $1,202,000 after buying an additional 33,647 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

RPRX has been the subject of several analyst reports. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. The Goldman Sachs Group began coverage on Royalty Pharma in a research note on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price objective on the stock. Citigroup boosted their price objective on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Royalty Pharma in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $47.20.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.